【分　 类】 医药卫生
【关 键 词】
【来 　源】 互联网
【收　 录】 中文学术期刊网

正文：

[5] Santillana E, Beceiro A, Bou G, et al. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. PNAS, 2007, 104(13):5354-5359.
[6] Hu WS, Yao SM, Fung CP, et al. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother, 2007, 51(11):3844-3852.
[7] Costa SF, Woodcock J, Gill M, et a1. Outer-membrane proteins pattern and detection of beta-lactamases in clinical isolates of imipenem-resistant Acin-etobacter baumannii from Brazil. Int J Antimicrob Agents, 2000, 13(3):175-182.
[8] Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol, 2002, 40(12):4776-4778.
[9] Dupont M, Pages JM, Lafitte D, et al. Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res, 2005, 4(6):2386-2390.
[10] Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev, 2003, 67(4):593-656.
[11] Altavilla D, Saitta A, Squadrito G, et al. Evidence for a role of nuclear factorkappaB in acute hypovolemic hemorrhagic shock. Surgery, 2006, 131 (12):50-58.
[12] Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii Strain BM4454. Antimicrob Agents Chemother, 2001, 45(12):3375-3380.
[13] Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev, 2008, 21(3):449-465.
[14] Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemothe r, 2011, 66(9):2070-2074.
[15] Kuo SC, Lee YT, Yang SP et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. Clin Microbiol Infect, 2012, 18(9):870-876.
[16] Bukhary Z, Mahmood W, Al-Khani A, et al. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J, 2005, 26(4):656-658.
[17] Kim BN, Peleg AY, Lodise TP et al. Management of meningitis due to antibiotic- resistant Acinetobacter species. Lancet Infect Dis, 2009, 9(4):245-255.
[18] Perez F, Hujer AM, Hujer KM, et al. Global Challenge of multidrug resi-stant Acinetobacter baumannii. Antimicrob Agents Chemother, 2007, 51(10):3471-3484.
[19] 王辉, 倪语星, 陈民钧, 等. 新型甘氨酰环素类抗菌药物替加环素体外药敏试验操作规程. 中华检验医学杂志, 2009, 32:1208-1213.
[20] Torrico M, González N, Giménez MJ, et al. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC. J Clin Microbiol, 2010, 48(6):2243-2246.
[21] 崔俊昌, 宋秀杰. 不同MH琼脂对于替加环素对鲍曼不动杆菌药敏结果的影响. 中国药物应用与监测, 2012, 9(2):84-86.
[22] Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother, 2007, 51(6):2065-2069.
[23] 罗燕萍, 沈定霞, 杨继勇, 等. 头孢哌酮/舒巴坦与2种抗菌药物联用对耐多药鲍氏不动杆菌药敏试验研究. 中华医院感染学杂志, 2008, 18(10):1431-1433.
[24] Cawley MJ, Suh C, Lee S, et al. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy, 2002, 22(4):527-532.
[25] Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, et al. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother, 2006, 58(3):689-692.
[26] TongW, Wang R, Chai D, et al. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. Int J Antimicrob Agents, 2006, 28(5):454-456.
[27] Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol, 2006, 46(10):1171-1178.
 

 3/3   首页 上一页 1 2 3